Home » Cagrilintide (10 mg Vial) Dosage Protocol

Cagrilintide (10 mg Vial) Dosage Protocol

Quickstart Highlights

Cagrilintide is a long-acting, modified version of the natural hormone amylin, formulated for once-weekly subcutaneous use. It works by activating amylin receptors in the brain, helping to increase feelings of fullness, slow down stomach emptying, and reduce overall food intake. Clinical studies have shown that it can lead to dose-dependent weight loss, with most side effects being mild and related to digestion.

Reconstitution: Add 3.0 mL of bacteriostatic water to achieve a concentration of approximately 3.33 mg/mL
Typical Weekly Dose: 0.6–4.5 mg once per week, gradually increased over 4–6 weeks
Measurement Guide: At this concentration, 1 unit (0.01 mL) equals about 0.033 mg (33.3 mcg) using a U-100 insulin syringe
Storage: Keep the lyophilized vial frozen at −20°C (−4°F). After mixing, store in the refrigerator (2–8°C) and use within 30 days

Dosing & Reconstitution Guide

Educational guide for reconstitution and daily dosing

Standard / Gradual Approach (3 mL = ~3.33 mg/mL)

Week / Phase	Weekly Dose (mg)	Units (per injection)	Volume (mL)
Phase 1	0.6 mg	12 units	0.12 mL
Phase 2	1.2 mg	24 units	0.24 mL
Phase 3	2.4 mg	48 units	0.48 mL
Phase 4 (Maintenance)	4.5 mg	90 units	.9 mL

Note: When taking with Semaglutide or Tirzepatide, you want to start at half the typical starting dose.

Start at 300 mcg (6 Units) and slowly increase your your dose.

Reconstitution Steps

Using a sterile syringe, draw up 2.0 mL of bacteriostatic water
Slowly inject the solution along the inner wall of the vial to minimize bubbling
Gently rotate or swirl the vial until the contents are fully dissolved — avoid shaking
Clearly label the vial with the date and final concentration, then store in the refrigerator at 2–8 °C (35.6–46.4 °F), away from light
Use within 30 days after mixing; discard if the solution appears cloudy or contains particles

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Supplies Needed

This plan is based on an 8–16 week protocol with once-weekly administration and gradual dose escalation.

Peptide Vials (Cagrilintide – 10 mg each):
• 8 weeks: ~2 vials (~17.4 mg total required)
• 12 weeks: ~4 vials (~35.4 mg total required)
• 16 weeks: ~6 vials (~53.4 mg total required)

Syringes:
• U-100 insulin syringes provide accurate dosing

• Usage: 1 syringe per week

• 8 weeks: 8 syringes
• 12 weeks: 12 syringes
• 16 weeks: 16 syringes

Bacteriostatic Water (10 mL bottles):
Each vial requires 2.0 mL for reconstitution

• 8 weeks (2 vials): 4 mL → 1 × 10 mL bottle
• 12 weeks (4 vials): 8 mL → 1 × 10 mL bottles
• 16 weeks (6 vials): 12 mL → 2 × 10 mL bottles

Alcohol Swabs:
Use one swab for the vial stopper and one for the injection site per administration

• Per week: 2 swabs
• 8 weeks: 16 swabs
• 12 weeks: 24 swabs
• 16 weeks: 32 swabs → 1 × 100-count box recommended

Protocol Overview

A simplified outline of the once-weekly research approach.

Goal: Support research into appetite control, reduced caloric intake, and long-term weight regulation pathways.
Schedule: Administer via subcutaneous injection once per week for approximately 12–16 weeks (or longer depending on study design).
Dose Range: Typically 0.6–4.5 mg per week, with gradual increases to assess response and tolerability.
Reconstitution: Add 2.0 mL bacteriostatic water to a 10 mg vial to achieve an approximate concentration of 2.5 mg/mL for easier measurement.
Storage: Store lyophilized product frozen; once reconstituted, keep refrigerated and avoid repeated freeze–thaw cycles.

Dosing Protocol

Example of a gradual weekly titration strategy:

Starting Dose: Begin with 0.6 mg once weekly for the first 2 weeks
Titration: Increase the dose every 2 weeks as tolerated (0.6 → 1.2 → 2.4 → 4.5 mg)
Target Dose: Reach 4.5 mg per week around Weeks 7–8, then maintain
Frequency: One subcutaneous injection per week
Timing: Administer on the same day each week at a consistent time; rotate injection sites regularly

Storage Instructions

Maintaining proper storage conditions is essential for stability.

Lyophilized: Keep at −20 °C (−4 °F) in a dry, light-protected environment
After Reconstitution: Store at 2–8 °C (35.6–46.4 °F) and use within 30 days

Avoid repeated freeze–thaw cycles
Allow the vial to reach room temperature before opening to reduce moisture buildup

Important Notes

Key considerations for consistency and safe handling:

Always use a new sterile syringe for each injection and dispose of it in a proper sharps container
Rotate injection sites (abdomen, thighs, upper arms) to minimize irritation
Gradual dose increases may help reduce common effects such as nausea during early stages
Keep a record of weekly dosing, injection sites, and any observed responses
For doses exceeding 1.0 mL, use a 3 mL syringe to ensure accurate administration

How This Works

Cagrilintide is a long-acting analog of the hormone amylin, which plays a role in appetite regulation and metabolic signaling. Amylin is naturally released alongside insulin and contributes to feelings of fullness after eating.

In research settings, Cagrilintide is studied for its ability to reduce appetite, slow gastric emptying, and influence energy intake. Its modified structure allows for an extended duration of action, making it suitable for once-weekly administration protocols.

Potential Benefits & Side Effects

Insights from research and clinical observations:

Potential Benefits

Supports appetite regulation and satiety signaling
May assist in reducing overall caloric intake
Studied for its role in weight management and metabolic balance
Long-acting profile allows less frequent administration

Possible Side Effects

Mild gastrointestinal responses such as nausea or discomfort (especially during early use)
Temporary changes in appetite
Occasional redness or irritation at the injection site

Note: Responses may vary depending on study conditions and dosage levels. Long-term data is still being evaluated.

Lifestyle Factors

Supporting variables that may improve research consistency:

Maintain a balanced, nutrient-dense diet aligned with study goals
Combine resistance and cardiovascular activity where applicable
Ensure adequate sleep and recovery
Stay properly hydrated, especially during early adjustment phases

Injection Technique

General guidance for subcutaneous administration:

Clean the vial stopper and injection area with alcohol and allow to dry
Gently pinch the skin and insert the needle at a 45–90° angle
Inject slowly and steadily without aspirating
Hold the needle in place for a few seconds before removing
Rotate injection sites (abdomen, thighs, upper arms) to reduce irritation

Recommended Source

We recommend Fit Aminos for high-purity Cagrilintide – 10mg

research peptide products.

Why Fit Aminos?

High-purity, lab-tested peptide batches with quality verification.
Consistent handling and preparation processes designed to support reliable research protocols.
Transparent sourcing and dependable fulfillment for research-grade compounds.

Shop Cagrilintide – 10mg at Fit Aminos

Important Note

This content is intended for educational and research purposes only and does not constitute medical advice, diagnosis, or treatment. Cagrilintide – 10mg remains an investigational peptide with limited human clinical data. For research use only. Not for human consumption.

References

The Lancet (2021) – Once‑weekly Cagrilintide for weight management: phase 2 dose‑finding trial (Lau et al.). This study evaluated different weekly doses and reported efficacy and tolerability in adults with overweight or obesity.

Int J Mol Sci (2024) – Amylin, another important neuroendocrine hormone for treatment of diabesity. This article discusses the role of amylin in regulating metabolism and energy balance.

PMC (2022) – Mediators of amylin action in metabolic control. Provides insights into the molecular mechanisms by which amylin analogs like Cagrilintide affect metabolic pathways.

The Lancet (2021) – Cagrilintide phase 2 trial: 10.8% weight loss at 4.5 mg dose over 26 weeks. Reports significant weight reduction at the highest tested dose with manageable side effects.

N Engl J Med (2025) – REDEFINE 1: Coadministered Cagrilintide and Semaglutide in adults with overweight or obesity. Shows combined therapy achieves greater weight loss than either agent alone.